[SCHEDULE 13D/A] IGM Biosciences, Inc. SEC Filing

Rhea-AI Filing Summary

Redmile Group and Jeremy C. Green amended their Schedule 13D to report participation in a completed merger of IGM Biosciences, Inc. Pursuant to a June 1, 2025 merger agreement, Merger Sub completed a tender offer that expired August 13, 2025, at an offer price of $1.247 per share plus one contingent value right (CVR) per share. Redmile and affiliated funds tendered all of their Issuer Shares, including 2,952,131 shares of Common Stock and 7,199,325 shares of Non-Voting Common Stock, and Redmile owned 667,666 pre-funded warrants immediately prior to closing. The merger closed on August 14, 2025, with IGM surviving as a wholly owned subsidiary of Parent and certain in-the-money equity awards settled for cash plus CVRs while out-of-the-money options were cancelled for no consideration.

Positive

• Redmile tendered 100% of its holdings in the offer, converting positions to cash and CVRs
• Offer price of $1.247 per share plus CVRs provides immediate liquidity and potential contingent upside
• Merger closed and IGM became a wholly owned subsidiary, completing the transaction

Negative

• Reporting persons ceased to be beneficial owners of >5% of the class as of August 14, 2025
• Out-of-the-money options were cancelled for no consideration, reducing potential equity value for some holders

Insights

M&A Specialist

TL;DR: A full tender by a major shareholder completed a cash+CVR acquisition, converting equity into immediate consideration and contingent upside.

The transaction delivered immediate cash consideration of $1.247 per share to Redmile and its funds and provided CVRs that preserve potential upside tied to post-closing cash and near-term product dispositions. Tendering 100% of Redmiles holdings simplifies post-close integration and removes activist or large-shareholder influence. Cancellation of out-of-the-money options is routine in cash deals, while treatment of pre-funded warrants and in-the-money options (cash plus CVR) preserves some upside for warrant/option holders. Overall, this is a tuck-in acquisition structure with contingent upside mechanisms aligned to specific deal economics.

Securities/Fund Analyst

TL;DR: Reporting persons realized liquidity and retained contingent value via CVRs but no longer hold >5% stake.

This amendment confirms Redmile and Jeremy Green ceased to beneficially own any reportable common stock following the closing, converting equity and exercisable instruments into cash payments plus CVRs. For fund-level investors, the outcome crystallizes realized proceeds and maintains limited contingent upside from the CVR formula tied to Closing Net Cash and certain near-term product monetizations. The disclosure is procedural and material to ownership tracking but indicates exit rather than increased strategic positioning.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

IGM Biosciences, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

449585108

(CUSIP Number)

Redmile Group, LLC
Attn: Joshua Garcia, One Letterman Drive Bldg D, Ste D3-300
San Francisco, CA, 94129
(415) 489-9980

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/14/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 449585108

1

Name of reporting person

Redmile Group, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person:

(1) The source of funds was working capital of certain private investment funds managed by Redmile Group, LLC (the "Redmile Funds"). (2) Percent of class is calculated based on 36,593,204 shares of Common Stock outstanding as of July 25, 2025 reported in the Issuer's quarterly report for the quarterly period ended June 30, 2025 on Form 10-Q as filed with the SEC on July 31, 2025 (the "Form 10-Q").

SCHEDULE 13D

CUSIP No. 449585108

1

Name of reporting person

Jeremy C. Green

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

IN, HC

Comment for Type of Reporting Person:

(1) The source of funds was working capital of the Redmile Funds. (2) Percent of class is calculated based on 36,593,204 shares of Common Stock outstanding as of July 25, 2025 reported in the Issuer's Form 10-Q.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.01 per share
(b)	Name of Issuer: IGM Biosciences, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3 East Third Avenue, Suite 200, San Mateo, CALIFORNIA , 94401.
Item 2.	Identity and Background
(a)	This amendment No. 7 to Schedule 13D (this "Amendment No. 7") amends and supplements the Schedule 13D filed with the SEC on September 24, 2019 (the "Original Schedule 13D"), as amended by that amendment No. 1 to Schedule 13D filed with the SEC on September 10, 2020, that amendment No. 2 to Schedule 13D filed with the SEC on December 15, 2020, that amendment No. 3 to Schedule 13D filed with the SEC on April 5, 2022, that amendment No. 4 to Schedule 13D filed with the SEC on October 5, 2022, that amendment No. 5 to Schedule 13D filed with the SEC on June 13, 2023, and that amendment No. 6 to Schedule 13D filed with the SEC on June 28, 2023 (hereinafter the Original Schedule 13D and such amendments shall collectively be referred to as the "Prior Schedule 13D"), in each case by Redmile Group, LLC, a Delaware limited liability company ("Redmile"), and Jeremy C. Green, a citizen of the United Kingdom (each, a "Reporting Person"), relating to the Common Stock of IGM Biosciences, Inc., a Delaware corporation (the "Issuer"). Capitalized terms used but not defined in this Amendment No. 7 shall have the meanings set forth in the Prior Schedule 13D. Except as specifically amended by this Amendment No. 7, the Prior Schedule 13D is unchanged.
Item 4.	Purpose of Transaction
	Item 4 of the Prior Schedule 13D is hereby amended and supplemented in its entirety by adding the following paragraphs prior to the last paragraph of Item 4: The Tender Offer and the Merger On August 14, 2025, pursuant to the terms of the previously announced agreement and plan of merger, dated June 1, 2025 (the "Merger Agreement"), by an among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), and Concentra Merger Sub V, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed its tender offer (the "Offer") to acquire all of the Issuer's issued and outstanding Common Stock and Non-Voting Common Stock (the "Issuer Shares") in exchange for (a) a price per share of $1.247 in cash (the "Offer Price"), subject to applicable tax withholding and without interest, plus (b) one contingent value right ("CVR") per share subject to the terms and conditions of the CVR Agreement described below (the "Purchase Price"). The Offer was subject to certain conditions, including among others that more than 50% of the Issuer's outstanding Common Stock be validly tendered in the Offer, inclusive of the shares of Common Stock owned by Parent and its affiliates. The Offer expired one minute following 11:59 p.m., Eastern Time, on August 13, 2025 (the "Offer Closing"). Redmile and the Redmile Funds tendered 100% of their Issuer Shares to Merger Sub by the Offer Closing in exchange for the aggregate Purchase Price. The Issuer Shares tendered by Redmile and the Redmile Funds included (a) 2,952,131 shares of Common Stock, and (b) 7,199,325 shares of Non-Voting Common Stock. On August 14, 2025, the Issuer completed the merger transaction with and into Merger Sub, with the Issuer surviving as a wholly owned subsidiary of Parent, pursuant to the terms of the Merger Agreement and applicable Delaware law (the "Merger"). At the effective time and date of the Merger (the "Merger Closing"), and without any action on the part of the Issuer stockholders, (a) each Issuer Share (other than those shares owned by (i) Parent, Merger Sub or any other Parent subsidiary after the Offer or (ii) any Issuer stockholders who are entitled to and who properly exercised their appraisal rights under Delaware law) automatically converted into the right to receive cash in the amount of the Offer Price; (b) each Pre-Funded Warrant was cancelled and the holder received the right to a cash amount based on the Offer Price, subject to applicable tax withholding and without interest, less the exercise price per share underlying the Pre-Funded Warrant, plus one CVR per underlying share subject to the terms and conditions of the CVR Agreement described below; (c) each in-the-money Option automatically vested and was cancelled and the holder received the right to a cash amount based on the Offer Price, subject to applicable tax withholding and without interest, less the exercise price per share underlying the Option, plus a CVR per underlying share subject to the terms and conditions of the CVR Agreement described below; and (d) each out-of-the-money Option was cancelled for no consideration. Immediately prior to the Merger Closing, Redmile beneficially owned 667,666 Pre-Funded Warrants, and all of the Options beneficially owned by Redmile were out-of-the-money. Immediately prior to the Offer Closing Time, Redmile beneficially owned 12,712 shares of Common Stock issued pursuant to fully vested RSUs granted to Michael Lee, a managing director of Redmile, in connection with his service as a member of the Issuer's Board of Directors. All of such shares were tendered in the Offer in exchange for the aggregate Purchase Price. Pursuant to the policies of Redmile, Mr. Lee held the Common Stock issued pursuant to the RSUs as a nominee on behalf, and for the sole benefit, of Redmile and its affiliates, and assigned all economic, pecuniary and voting rights in respect of the Common Stock issued pursuant to the RSUs to Redmile. Redmile and Mr. Green each disclaim beneficial ownership of such securities, except to the extent of its or his pecuniary interest in such securities, if any, and this Schedule 13D shall not be deemed an admission that the Reporting Persons are the beneficial owner of such securities any purpose. In connection with the Merger, Parent, Merger Sub and a rights agent entered into a contingent value rights agreement (the "CVR Agreement"), which provides that each CVR represents a contractual right to receive contingent cash payments equal to: (i) 100% of the amount by which Closing Net Cash (as finally determined pursuant to the Merger Agreement) exceeds $82.0 million, adjusted for any claims Parent reasonably determines to be valid five business days prior to the Merger Closing Date (as defined in the Merger Agreement) and that are not accounted for in such Closing Net Cash; and (ii) 80% of the Net Proceeds (as defined in the CVR Agreement), if any, from any sale, transfer, license or other disposition or grant of rights by Parent or any of its affiliates of all or any part of certain products and patents of the Issuer that occurs within the period beginning on the Merger Closing Date and ending on the first anniversary thereof. The foregoing descriptions of the Merger Agreement and the CVR Agreement do not purport to be complete and are qualified in their entirety by reference to the Merger Agreement and Form of CVR Agreement, copies of which are filed as Exhibit 2.1 and Exhibit 10.1, respectively, in the Issuer's Form 8-K filed on July 1, 2025 and are incorporated herein by reference. Resignation of Mike Lee from the Board of Directors Pursuant to the terms of the Merger Agreement, Michael Lee resigned from the Issuer's Board of Directors effective immediately prior to the Merger Closing.
Item 5.	Interest in Securities of the Issuer
(a)	Redmile: (1) Aggregate Number of Common Stock Beneficially Owned: 0 (2) Aggregate Percentage of Common Stock Beneficially Owned: 0.0% Jeremy C. Green: (1) Aggregate Number of Common Stock Beneficially Owned: 0 (2) Aggregate Percentage of Common Stock Beneficially Owned: 0.0%
(b)	Redmile: (1) Sole Voting Power: 0 (2) Shared Voting Power: 0 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 0 Jeremy C. Green: (1) Sole Voting Power: 0 (2) Shared Voting Power: 0 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 0
(c)	See the response to Item 4. Except as disclosed in Item 4, no reportable transactions were effected by any Reporting Persons during the past sixty days.
(e)	As of August 14, 2025, the Reporting Persons ceased to be the beneficial owners of more than five percent of the class of securities.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information in Item 4 is incorporated herein by reference.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Redmile Group, LLC

Signature:	/s/ Jeremy C. Green
Name/Title:	Managing Member
Date:	08/15/2025

Jeremy C. Green

Signature:	/s/ Jeremy C. Green
Name/Title:	Jeremy C. Green
Date:	08/15/2025

FAQ

What did Redmile report in the IGM Biosciences (IGMS) Schedule 13D/A?

The filing reports that Redmile Group and Jeremy C. Green tendered all issued shares they held in the August 2025 tender offer and that the merger closed on August 14, 2025.

What was the cash consideration per share paid in the tender offer for IGMS?

The Offer Price paid was $1.247 per share, subject to tax withholding and without interest.

Did Redmile receive any contingent consideration in the IGM transaction?

Yes. Each share received one contingent value right (CVR) that can pay based on Closing Net Cash above $82.0 million and 80% of certain near-term net proceeds from specified product or patent dispositions within one year.

How many shares did Redmile tender in the offer?

Redmile and the Redmile Funds tendered 2,952,131 shares of Common Stock and 7,199,325 shares of Non-Voting Common Stock.

What happened to IGM stock options and pre-funded warrants at closing?

Pre-funded warrants held by Redmile (667,666) were converted for cash plus CVRs; in-the-money options were cashed out for cash plus CVRs; out-of-the-money options were cancelled for no consideration.